Printer Friendly

ANTIVIRALS NAMES BURGER PRESIDENT

 ANTIVIRALS NAMES BURGER PRESIDENT
 CORVALLIS, Ore., Feb. 26 /PRNewswire/ -- Denis R. Burger, Ph.D.,


age 48, has been named president and chief operating officer of Antivirals Inc., a privately held Oregon corporation, effective Feb. 18, the company announced today. In addition, he will retain his duties as a member of the board of directors.
 Burger has served on the Antivirals board since November 1991, when the company expanded its board of directors and initiated expansion of its management team.
 Burger was the co-founder of Epitope Inc. (AMEX: EPT) in 1979 and served as its chairman until leaving the company in 1990. At Epitope, he was responsible for the company's initial private and public financings and its research and development program. In addition, he was responsible for attracting Epitope's current senior management and directors.
 Prior to entering the biotech industry, Burger was professor of Microbiology and Immunology and associate professor of Surgery at the Oregon Health Sciences University and career scientist at the Portland V.A. Medical Center.
 "Denis Burger has the vision and management expertise to transform technology into products for clinical use. I am eager to work with him in his new role as president," stated Dr. James Summerton, founder of Antivirals and chairman of the board.
 Antivirals Inc. is the pioneer company and the technological leader in the emerging field of "antisense" therapeutics. The company's work is focused on developing novel therapeutic drugs to treat a broad range of viral diseases, including AIDS, Herpes, Hepatitis and Influenza. Commonly referred to as antisense, these gene-inactivating agents specifically bind to selected viral genetic sequences to inactivate the targeted viruses. When developed fully, these agents are expected to be safe, effective therapeutics for most or all viral diseases. They are also expected to prove effective for treating cancers and possibly autoimmune disorders.
 -0- 2/26/92
 /CONTACT: Connie Hensley-Jones of Antivirals, 503-753-3635/
 (EPT) CO: Antivirals Inc. ST: Oregon IN: MTC SU: PER


SC-JH -- SE001 -- 2787 02/26/92 12:05 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 26, 1992
Words:330
Previous Article:SOUTHMARK RECEIVES PAYMENTS FROM TWO MAJOR SETTLEMENTS
Next Article:CYTRX ANNOUNCES EXERCISE OF CLASS B WARRANTS
Topics:


Related Articles
BURGER KING NAMES ADAMSON PRESIDENT, USA RETAIL DIVISION
ANTIVIRALS APPOINTS WILLIAM FLEMING DIRECTOR OF CORPORATE DEVELOPMENT
RICHARD N. BURGER NAMED PRESIDENT AND CEO OF BURNS AEROSPACE CORPORATION
ANTIVIRALS INC. APPOINTS ALAN P. TIMMINS CHIEF FINANCIAL OFFICER
ANTIVIRALS INC. ANNOUNCES THREE NEW ANTISENSE PATENTS ISSUED
TRINITY BIOTECH SELECTS DR. ANTHONY NICHOLLS AS NEW CHAIRMAN
Biota Values Claim Against GSK at A$308 to A$430 Million.
Biota Values Claim Against GSK at A$308 to A$430 Million.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters